表紙
市場調查報告書
商品編碼
1039997

婦產科癌症治療藥的全球市場:2021年∼2028年

Global Gynecological Cancers Therapeutics Market - 2021-2028

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球婦產科癌症治療藥市場,婦產科癌症的發生率高,標的藥物療法的重要性高漲,對癌症治療的開發新藥的政府和公共機關及民間團體的投資擴大,導致癌症的危險因素增加等推動成長要素。

在婦產科癌症的治療相關開發平台上,有標靶治療藥,基因治療,疫苗等。標靶治療藥和疫苗處於臨床開發的後期階段,而基因治療處於初期階段。美國 FDA 等監管機構已核可用於治療婦科癌症的治療劑。因此,預計在預測期內,新藥的強大管道和核可將推動市場成長。

本報告提供全球婦產科癌症治療藥市場相關調查,市場概要,以及各治療,各癌症類型,各終端用戶,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 全球婦產科癌症治療藥市場調查手法和範圍

  • 調查手法
  • 調查的目的和調查範圍

第2章 全球婦產科癌症治療藥市場-市場定義和概要

第3章 全球婦產科癌症治療藥市場-摘要整理

  • 各癌症類型的市場明細
  • 各治療的市場明細
  • 各終端用戶的市場明細
  • 各地區的市場明細

第4章 全球婦產科癌症治療藥市場-市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球婦產科癌症治療藥市場-產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 全球婦產科癌症治療藥市場-COVID-19分析

  • 市場上COVID-19分析
    • COVID-19前的市場情境
    • COVID-19目前市場情境
    • COVID-19後或未來情境
  • COVID-19的價格動態
  • 需求與供給的頻譜
  • 大流行時的市場相關的政府舉措
  • 製造商策略性舉措
  • 結論

第7章 全球婦產科癌症治療藥市場-各癌症類型

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%),各癌症類型
    • 市場魅力指數,各癌症類型
  • 子宮癌
    • 簡介
    • 市場規模分析,100萬美元,2018年∼2028年,及與前一年同期比較成長分析(%),2020年∼2028年
  • 卵巢癌
  • 陰道癌、外陰癌
  • 子宮頸癌

第8章 全球婦產科癌症治療藥市場-各治療

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%),各治療
    • 市場魅力指數,各治療
  • 標靶治療
    • 簡介
    • 市場規模分析,100萬美元,2018年∼2028年,及與前一年同期比較成長分析(%),2020年∼2028年
  • 化療
  • 免疫療法
  • 荷爾蒙療法

第9章 全球婦產科癌症治療藥市場-各終端用戶

  • 簡介
    • 市場規模分析,及與前一年同期比較成長分析(%),各終端用戶
    • 市場魅力指數,各終端用戶
  • 醫院
    • 簡介
    • 市場規模分析,100萬美元,2018年∼2028年,及與前一年同期比較成長分析(%),2020年∼2028年
  • 癌症中心
  • 診所
  • 門診病人手術中心
  • 其他

第10章 全球婦產科癌症治療藥市場-各地區

  • 簡介
    • 市場規模分析,100萬美元,2018年∼2028年,及與前一年同期比較成長分析(%),2020年∼2028年,各地區
    • 市場魅力指數,各地區
  • 北美
    • 簡介
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%),各癌症類型
    • 市場規模分析,及與前一年同期比較成長分析(%),各治療
    • 市場規模分析,及與前一年同期比較成長分析(%),各終端用戶
    • 市場規模分析,及與前一年同期比較成長分析(%),各國
  • 歐洲
    • 簡介
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%),各癌症類型
    • 市場規模分析,及與前一年同期比較成長分析(%),各治療
    • 市場規模分析,及與前一年同期比較成長分析(%),各終端用戶
    • 市場規模分析,及與前一年同期比較成長分析(%),各國
  • 南美
    • 簡介
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%),各癌症類型
    • 市場規模分析,及與前一年同期比較成長分析(%),各治療
    • 市場規模分析,及與前一年同期比較成長分析(%),各終端用戶
    • 市場規模分析,及與前一年同期比較成長分析(%),各國
  • 亞太地區
    • 簡介
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%),各癌症類型
    • 市場規模分析,及與前一年同期比較成長分析(%),各治療
    • 市場規模分析,及與前一年同期比較成長分析(%),各終端用戶
    • 市場規模分析,及與前一年同期比較成長分析(%),各國
  • 中東、非洲
    • 簡介
    • 主要地區具體動態
    • 市場規模分析,及與前一年同期比較成長分析(%),各癌症類型
    • 市場規模分析,及與前一年同期比較成長分析(%),各治療
    • 市場規模分析,及與前一年同期比較成長分析(%),各終端用戶

第11章 全球婦產科癌症治療藥市場-競爭情形

  • 主要的發展與策略
  • 企業佔有率分析
  • 產品的基準
  • 值得注意的主要企業
  • 顛覆性技術的企業
  • Start-Ups企業

第12章 全球婦產科癌症治療藥市場-企業簡介

  • F. Hoffmann-La Roche Ltd
    • 企業概要
    • 產品系列和概要
    • 主要的焦點
    • 財務概要
  • Novartis AG
  • Eli Lilly and Company
  • AstraZeneca
  • Merck & Co., Inc
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd
  • Apotex Inc

非詳細列表

第13章 全球婦產科癌症治療藥市場-DataM

  • 附錄
  • 關於本公司、服務
  • 諮詢方式
目錄
Product Code: DMPH4357

Market Overview

The global gynecological cancers therapeutics market size was worth US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Cancer refers to a specific group of disorders, which leads to abnormal cell growth within any part of the body. Gynecological cancer refers to a group of cancers that affect the reproductive organs, such as uterus, endometrium, ovary, peritoneum, fallopian tubes, vagina, vulva, cervix, and muscle & tissue supporting the uterus.

Market Dynamics

The global gynecological cancers therapeutics market growth is driven by the high incidence of gynecological cancers, rise in importance of targeted drug therapies, rise in investment from government, public & private organizations for the development of novel drugs to treat cancer, and increase in risk factors that lead to cancer drive the market growth.

Growing robust pipeline of novel drugs is expected to drive the growth in the forecast period

The presence of a robust pipeline, new drug approvals, and the availability of advanced diagnostic modalities are anticipated to boost the market's growth.

The pipeline for the treatment of gynecological cancers includes targeted therapy products, gene therapy, and vaccines. Targeted therapy products and vaccines are in the late stages of clinical development, while gene therapy is early. These products are innovative in terms of advanced therapeutic mechanisms of action such as PARP inhibition, cell cycle inhibition, programmed death-ligand 1 (PD-L1) inhibition, and angiogenesis inhibition and are expected to change the course of gynecological cancer treatment. Furthermore, regulatory agencies such as the US FDA are granting approvals for therapeutics indicated for the treatment of gynecological cancers. For instance, Olaparib, manufactured by AstraZeneca under the brand name LYNPARZA, was approved in December 2018. Thus, a strong pipeline and approval of new drugs are expected to drive market growth during the forecast period.

Furthermore, the availability of advanced diagnostic modalities ensures an appropriate diagnosis of the disease by identifying targets for therapies. With the possibility of the early detection of gynecological cancer, the demand for diagnostic tools such as DNA microarray, complementary DNA fingerprinting, molecular profiling, and polymerase chain reaction to diagnose cancer in its early stage is increasing. This will drive the gynecological cancers therapeutics market to grow at a highest CAGR during the forecast period.

High cost of treatment and threat of failure & adverse effects of cancer drug therapy is likely to hamper the market growth

The direct costs associated with the initial screening, diagnostic procedures, counseling, outpatient visits, surgery, inpatient charges, palliative care, and emergency services and the indirect fees, including absence from work and premature death, had contributed to the overall high cost of treatment. Additionally, adverse effects of cancer drug therapy like neutropenia, lymphedema, alopecia, nausea, deep vein thrombosis etc are likely to restrain the market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has negatively impacted healthcare systems globally and also on the market growth. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the On-going clinical trials too. However, the situation is expected to improve gradually.

Segment Analysis

The chemotherapy segment is expected to hold the largest share in this market segment

The chemotherapy segment accounted for the largest market share and is expected to maintain this trend throughout the forecast period. In recent years, combination chemotherapy has been considered a standard treatment mode for cancer treatment due to its effectiveness in an increase in survival & remission rates. For instance, combination therapy of gemcitabine with a platinum compound produced high response rates (as high as 71%) in patients suffering from ovarian cancer. Similarly, gemcitabine is used in combination with other compounds and cytotoxic agents to treat ovarian cancer effectively. Popular varieties include gemcitabine with a platinum compound and paclitaxel and gemcitabine with cisplatin or carboplatin. However, the standard approach of combination chemotherapy for the treatment of epithelial ovarian cancer has a combination of a platinum compound, such as cisplatin or carboplatin, and a taxane, such as paclitaxel (Taxol) or docetaxel (Taxotere).

Geographical Analysis

North America region holds the largest market share of global gynecological cancers therapeutics market

North America served the largest share of the market due to the increasing prevalence of cancer cases. The prime reason for the market's growth in this region is the rising incidence of the disease and the growing awareness among the general population. According to the American Cancer Society estimates that in 2020, around 65,620 new cases of uterine body cancer in the United States. Furthermore, about 10% of uterine body cancers are rare sarcoma. increasing incidences of cervical cancer and growing research and development activities by various healthcare regulatory organizations in this region. For instance, according to the American Cancer Society's (ACS) estimates for cervical cancer in the U.S. for 2018, around 13, 240 new cases of invasive cervical cancer were diagnosed, and around 4,170 women are expected to die from cervical cancer. Moreover, increase in funding by American Cancer Society, in March 2018, funded approximately 22 grants for cervical cancer, which accounted for around US$ 9.3 million. The funding value is offered to a single or group of research, including a specific type of cancer or area of cancer.

Competitive Landscape

The global gynecological cancers therapeutics market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include AstraZeneca, Bristol-Myers Squibb Company, F. Hoffmann-La Roche, GlaxoSmithKline plc, Merck & Co., Inc, Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd., Apotex Inc and Eli Lilly and Company.

Global Gynecological Cancers Therapeutics Market - Key Companies to Watch

F. Hoffmann-La Roche Ltd

Company Overview: Roche was founded in 1896 in Basel, Switzerland. It creates innovative medicines and diagnostic tests that help millions of patients globally. Roche was one of the first companies to bring targeted treatments to patients. With combined strength in pharmaceuticals and diagnostics, they are better equipped than any other company to drive personalized healthcare further. Two-thirds of their research and development projects are being developed with companion diagnostics. Genentech become a member of the Roche Group in March of 2009. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Product Portfolio: The company portfolio includes Bevacizumab (Avastin) belongs to a class of drugs called angiogenesis inhibitors. The company offers AVASTIN, which is indicated in combination with carboplatin and paclitaxel.

Why Purchase the Report?

Visualize the composition of the gynecological cancer therapeutics market segmentation by therapy, cancer type, end-user and region highlighting the key commercial assets and players.

Identify commercial opportunities in gynecological cancers therapeutics market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of gynecological cancers therapeutics market - level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global gynecological cancers therapeutics market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global Gynecological Cancers Therapeutics Market - By Therapy

Targeted Therapy

Avastin

Lynparza

Zejula

Rubraca

Vitrakvi

Tivdak

Votrient

Chemotherapy

Dacarbazine (DTIC)

Epirubicin (Ellence)

Gemcitabine (Gemzar)

Paclitaxel (Taxol)

Platinol

Paraplatin

Immunotherapy

Keytruda

Hormonal Therapy

Goserelin (Zoladex)

Leuprolide (Lupron)

Megestrol (Megace)

Tamoxifen

Anastrozole (Arimidex)

Global Gynecological Cancers Therapeutics Market - By Cancer Type

Uterine Cancer

Ovarian Cancer

Vaginal & Vulvar Cancer

Cervical Cancer

Global Gynecological Cancers Therapeutics Market - By End-user

Hospitals

Cancer Centers

Clinics

Ambulatory Surgical Centers

Others

Global Gynecological Cancers Therapeutics Market - By Region

North America

Europe

Asia-Pacific

Middle East & Africa

South America

Table of Contents

1. Global Gynecological Cancers Therapeutics Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Gynecological Cancers Therapeutics Market - Market Definition and Overview

3. Global Gynecological Cancers Therapeutics Market - Executive Summary

  • 3.1. Market Snippet by Cancer Type
  • 3.2. Market Snippet by Therapy
  • 3.3. Market Snippet by End-user
  • 3.4. Market Snippet by Region

4. Global Gynecological Cancers Therapeutics Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing robust pipeline of novel drugs
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of treatment and threat of failure & adverse effects of cancer drug therapy
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Gynecological Cancers Therapeutics Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Gynecological Cancers Therapeutics Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Gynecological Cancers Therapeutics Market - By Cancer Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 7.1.2. Market Attractiveness Index, By Cancer Type
  • 7.2. Uterine Cancer*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Ovarian Cancer
  • 7.4. Vaginal & Vulvar Cancer
  • 7.5. Cervical Cancer

8. Global Gynecological Cancers Therapeutics Market - By Therapy

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Segment
    • 8.1.2. Market Attractiveness Index, By Therapy Segment
  • 8.2. Targeted Therapy*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
    • 8.2.3. Avastin
    • 8.2.4. Lynparza
    • 8.2.5. Zejula
    • 8.2.6. Rubraca
    • 8.2.7. Vitrakvi
    • 8.2.8. Tivdak
    • 8.2.9. Votrient
  • 8.3. Chemotherapy
    • 8.3.1. Dacarbazine (DTIC)
    • 8.3.2. Epirubicin (Ellence)
    • 8.3.3. Gemcitabine (Gemzar)
    • 8.3.4. Paclitaxel (Taxol)
    • 8.3.5. Platinol
    • 8.3.6. Paraplatin
  • 8.4. Immunotherapy
    • 8.4.1. Keytruda
  • 8.5. Hormonal Therapy
    • 8.5.1. Goserelin (Zoladex)
    • 8.5.2. Leuprolide (Lupron)
    • 8.5.3. Megestrol (Megace)
    • 8.5.4. Tamoxifen
    • 8.5.5. Anastrozole (Arimidex)

9. Global Gynecological Cancers Therapeutics Market - By End-user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user Segment
    • 9.1.2. Market Attractiveness Index, By End-user Segment
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Cancer Centers
  • 9.4. Clinics
  • 9.5. Ambulatory Surgical Centers
  • 9.6. Others

10. Global Gynecological Cancers Therapeutics Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user

11. Global Gynecological Cancers Therapeutics Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. Key Companies to Watch
  • 11.5. Company with disruptive technology
  • 11.6. Start Up Companies

12. Global Gynecological Cancers Therapeutics Market- Company Profiles

  • 12.1. F. Hoffmann-La Roche Ltd*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Novartis AG
  • 12.3. Eli Lilly and Company
  • 12.4. AstraZeneca
  • 12.5. Merck & Co., Inc
  • 12.6. Bristol-Myers Squibb Company
  • 12.7. GlaxoSmithKline plc
  • 12.8. Pfizer Inc
  • 12.9. Teva Pharmaceutical Industries Ltd
  • 12.10. Apotex Inc

LIST NOT EXHAUSTIVE

13. Global Gynecological Cancers Therapeutics Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us